D'Angelo, Sandra

Publications

Sort by

Co-Author Network

selected publications

PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials. Journal of hematology & oncology. 2020 Letter GET IT
Times cited: 30
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 110
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. JAMA oncology. 2020 Academic Article GET IT
Times cited: 92
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Academic Article GET IT
Times cited: 90
Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Academic Article GET IT
Times cited: 7
Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. JAMA oncology. 2018 Academic Article GET IT
Times cited: 293
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. Journal for immunotherapy of cancer. 2018 Academic Article GET IT
Times cited: 245
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 343
Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. The Journal of thoracic and cardiovascular surgery. 2017 Academic Article GET IT
Times cited: 80
Patient perspectives on ipilimumab across the melanoma treatment trajectory. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2017 Academic Article GET IT
Times cited: 12
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 92
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 354
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 925
Current status of engineered T-cell therapy for synovial sarcoma. Immunotherapy. 2016 Review GET IT
Times cited: 12
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 114
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial. JAMA oncology. 2016 Academic Article GET IT
Times cited: 201
Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma. Sarcoma. 2016 Academic Article GET IT
Times cited: 693
Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations. The American journal of surgical pathology. 2016 Academic Article GET IT
Times cited: 132
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. 2016 GET IT
Times cited: 217
Reply to A. Indini et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Letter GET IT
Manipulating the Immune System With Checkpoint Inhibitors for Patients With Metastatic Sarcoma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2016 Review GET IT
Times cited: 10
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas. The oncologist. 2015 Academic Article GET IT
Times cited: 23
Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas. European journal of cancer (Oxford, England : 1990). 2015 Academic Article GET IT
Times cited: 69
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 749
Corrigendum to "Sarcoma Immunotherapy: Past Approaches and Future Directions". Sarcoma. 2015 Article GET IT
Times cited: 1
Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma. Oncology. 2015 Academic Article GET IT
Times cited: 34
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. Sarcoma. 2015 Academic Article GET IT
Times cited: 63
Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. The New England journal of medicine. 2015 Letter GET IT
Times cited: 53
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. The Lancet. Oncology. 2015 Academic Article GET IT
Times cited: 2090
Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma. Cancer chemotherapy and pharmacology. 2015 Academic Article GET IT
Times cited: 23
Soft tissue tumors of the trunk: management of local disease in the breast and chest and abdominal walls. Journal of surgical oncology. 2014 Review GET IT
Times cited: 19
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Human pathology. 2014 Academic Article GET IT
Times cited: 212
Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. The American journal of surgical pathology. 2014 Academic Article GET IT
Times cited: 118
Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation. Clinical lung cancer. 2014 Academic Article GET IT
Times cited: 52
Sarcoma immunotherapy: past approaches and future directions. Sarcoma. 2014 Review GET IT
Times cited: 41
High-risk features in radiation-associated breast angiosarcomas. British journal of cancer. 2013 Academic Article GET IT
Times cited: 48
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013 Academic Article GET IT
Times cited: 150
Ipilimumab for patients with advanced mucosal melanoma. The oncologist. 2013 Academic Article GET IT
Times cited: 125
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 330
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012 Academic Article GET IT
Times cited: 148
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 444
Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Cancer. 2012 Academic Article GET IT
Times cited: 46
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 231
A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed. 2011 GET IT
Times cited: 14
Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Academic Article GET IT
Times cited: 109
[The molecular pathogenesis of small cell lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2010 Review GET IT
Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center. The Journal of thoracic and cardiovascular surgery. 2010 Academic Article GET IT
Times cited: 30
The molecular pathogenesis of small cell lung cancer. Cancer biology & therapy. 2010 Review GET IT
Times cited: 40
Hepatitis C virus infection does not preclude standard breast cancer-directed therapy. Clinical breast cancer. 2009 Academic Article GET IT
Times cited: 5

more ...

less ...

Background

education and training

M.D., State University of New York Health Science Center at Brooklyn 2004
B.A., New York University 2000

Contact

full name

Sandra D'Angelo

VIVO Weill Cornell Medical College

Sandra D'Angelo Associate Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name